--(BUSINESS WIRE)--CyanVac LLC, a clinical-stage biotechnology company developing intranasal vaccines ... administered to dogs as part of combination distemper/kennel cough vaccines for decades.

As whooping cough cases rise in the U.S., a new nasal vaccine ... Current pertussis vaccines are widely used and effective at preventing whooping cough, caused by the Bordetella pertussis bacteria.

PIV5 has been commonly administered to dogs as part of combination distemper/kennel cough vaccines for decades. Blue Lake Biotechnology is developing BLB201 as an intranasal vaccine to prevent ...

The good news is that there’s a vaccine that can significantly reduce the chances of your dog catching kennel cough. This vaccine is often required by kennels and boarding facilities ...

are developing intranasal vaccines that harness the full breadth of the immune system to keep ... virus that is not known to cause disease in humans which has been commonly administered to dogs as ...

December 09, 2024--(BUSINESS WIRE)--CyanVac LLC, a clinical-stage biotechnology company developing intranasal ... administered to dogs as part of combination distemper/kennel cough vaccines ...

--(BUSINESS WIRE)--CyanVac LLC, a clinical-stage biotechnology company developing intranasal vaccines using a transformational parainfluenza ... known to cause disease in humans which has been ...

PIV5 has been commonly administered to dogs as part of combination distemper/kennel cough vaccines for decades. Blue Lake Biotechnology is developing BLB201 as an intranasal vaccine to prevent acute ...

Repeated sneezing is an early indicator of respiratory irritation caused by kennel cough. This reflex helps the dog’s body expel irritants from the nasal passages. If sneezing is accompanied by other ...

The collaboration will leverage Orexo’s scalable AmorphOX powder-based drug delivery technology and Abera’s expertise in vaccine development. As a first step, the companies will work on developing ...

December 12, 2024--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full ...